Log In
BCIQ
Print this Print this
 

YH25448

  Manage Alerts
Collapse Summary General Information
Company Yuhan Corp.
DescriptionThird-generation tyrosine kinase inhibitor (TKI) targeting the initial EGFR-activating mutation and the T790M EGFR resistance mutation
Molecular Target Epidermal growth factor receptor (EGFR)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat non-small cell lung cancer (NSCLC)
Regulatory Designation
PartnerShandong Luoxin Pharmaceutical Group Stock Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$126.0M

$6.0M

$120.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/28/2016

$126.0M

$6.0M

$120.0M

Get a free BioCentury trial today